BIT225 Opportunity Summary
BIT225 is a very important clinical asset for Biotron
• Previous positive clinical trial data have significantly de-risked the program
• Clear clinical development program designed to demonstrate to regulators and pharma how the drug may be
used to improve health outcomes in combination with ART
• SARS-CoV-2/COVID-19 program provides further value for BIT225 with results from the completed Phase 2
COVID-10 clinical trial expected shortly
• Results from three Phase 2 trials will be significant near-term milestones
• Positive data from these trials across two different disease indications will put the Company in a strong
position as it moves to partner the programs in 2024
• Pipeline of earlier stage, high value programs provide a solid base and potential future value for the Company
SARS-CoV-2/COVID-19 program provides further value for BIT225 with results from the completed Phase 2
COVID-10 clinical trial expected shortly
looks like a real winner to me Hang in there for a TH
BIT225 Opportunity SummaryBIT225 is a very important clinical...
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.001(1.89%) |
Mkt cap ! $48.72M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $6.98K | 133.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 151165 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 86242 | 1 |
View Market Depth
| Last trade - 15.32pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.2¢ |
Change
0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 5.3¢ | 5.3¢ | 5.2¢ | 38302 | ||
| Last updated 11.25am 24/05/2024 ? | |||||
| BIT (ASX) Chart |